Application Releases

March 21, 2012 | More effective drug screening now possible with in vitro cell models that come with their own reporter genes

SIRION BIOTECH launches SenCELLTM at Bio-Europe Spring in Amsterdam

Munich, Germany, SIRION Biotech presents its new line of products under the new SenCELL™ brand for functionality testing in stable in vitro cell systems.

An example is SenCELL LifeActTM representing a range of First in Class Sensor Cell Lines with sensor molecules that identify actin dynamics and at the same time show no interference with dynamic processes during cytoskeleton rearrangements. In detail, SenCELL LifeActTM express a small actin binding protein domain coupled to a fluorescent protein. This way, live cell imaging and high content analysis are now applicable to a wide variety of assays including migration assays using chemoattractants. The cell lines are functionally validated, available in bulk and shipped in frozen cell stocks. Applicable in a matter of days.

Press release in English

March 18, 2012 | Munich experts to discuss novel in vitro cell models

Munich, Germany:  More than 20 scientists met in early March at IZB Martinsried near Munich to discuss ways of further improving in vitro cell models. Modern preclinical research would not anymore exist without them.

Key issues remain with regard to predictivity as there continues to be a lack of advanced cell lines resembling in vivo conditions. Instead, easy to handle cancer cell lines are often being used. Also, there are limitations with traditional 2D cell cultures.

Press release in English

February 03, 2012 | AdenoONE™ makes working with adenovirus a standard procedure 

Adenovirus vector cloning and production still remain tricky with rather low yields and limited success. The brand new AdenoONE™ line of support kits turns cloning & production into an easy to schedule project step of less than 4 weeks. AdenoONE™ comprises 2 discrete kits: AdenONE™ Cloning Kit and AdenoONE™ Purification Kit. The latter allows for reliable purification within just 20 minutes. Soon will SIRION BIOTECH, also referred to as Munich’s “Cell Competence Center”, launch the AdenoONE™ Purification Kit in vivo.

Press release in English

October 24, 2011 | InSphero AG and SIRION BIOTECH GmbH announce Development & Marketing cooperation on 3D-based cell models

InSphero AG and SIRION BIOTECH GmbH, two privately-held biotech com-panies based in Zurich and Martinsried near Munich, respectively, announced today an agreement allowing for a close cooperation on the development and the promotion of most innovative cell models in the form of three-dimensional (3D) microtissues.

Press release in English


JUNE 24, 2010 | TET Systems and SIRION BIOTECH GmbH sign a commercial license agreement

TET Systems (TET) and SIRION BIOTECH GmbH, two privately-held, German biotech companies based in Heidelberg and Martinsried near Munich, respectively, announced today that they have signed a commercial license agreement. Under the terms of the agreement, SIRION BIOTECH offers customized services to its clients using the Tet Technology to generate cell lines and to generate and manufacture recombinant viral vector products.

Press release in English
Press release in German


MARCH 25, 2010 | Helmholtz Zentrum München and SIRION BIOTECH Initiate Research Cooperation to Develop New Anti-Cancer Gene Therapy Approach Using Lentiviral Vectors

Helmholtz Zentrum München has launched a new cooperative project with SIRION BIOTECH GmbH in Martinsried to develop new therapeutic approaches against lymphoid tumors. With a two-year grant from the Federal Ministry for Economics and Technology, the two partners will seek to further develop lentiviral vector systems to better understand the disease mechanisms of this cancer form and to devise approaches for treatment.

Press release in English
Press release in German


Jan 2010 | SIRION BIOTECH and Sigma-Aldrich entered into a service agreement

under which SIRION BIOTECH provides custom shRNA knockdown cell lines, utilizing validated The RNAi Consortium (TRC) shRNA RNAi libraries from Sigma Life Science. First of all the offer is limited to the German research community.


Jan 2010 | SIRION BIOTECH becomes industry partner of the FORPROTECT „Neue Genom-basierte Diagnostikverfahren und Therapieansätze zur Bekämpfung von Infektionskrankheiten“  with Dr. Christian Thirion, CSO of the company, being the speaker of this new alliance to fight infectious diseases

By identifying the antigen profiles in the natural in vivo milieu of infectious bacteria the alliance will develop new diagnostic and immunization strategies. Part of the project is also to develop more sophisticated T-Zell analysis for improved epitope maps of viral deseases.


Jan 2010 | SIRION BIOTECH successfully completes a test phase with more than 80 test sites for its new product TransMAX, an enhancer of adenovirus uptake, and launches TransMAX

The test customers detected up to 50 fold enhanced expression rates depending on the cell type. In addition, TransMAX has been shown to now enable gene transfer to human dendritic cells, mouse embryonic stem cell or skeletal muscle cells having a wide impact on the corresponding scientific areas.


Oct 2009 | SIRION BIOTECH together with Helmholtz Zentrum Munich (HGMU) receives funding from BMWi for finding new therapeutic approaches in leukemia

In the two years cooperation project funded with approx. 300 tEUR SIRION BIOTECH will facilitate viral delivery of siRNAs to hematopoietic cells which HGMU will use for target validation in leukemia research.


FEB 2007 | Contract research business for biotech and pharma started.


JUN 2006 | SIRION GmbH filed patent

SIRION GmbH filed patent for its proprietary Q-tech technology.


APR 2006 | SIRION GmbH signed license agreement with CCS GmbH

SIRION GmbH signed license agreement for storage and shipment technology with CCS GmbH, Hamburg.



SIRION BIOTECH GmbH | Am Klopferspitz 19 | 82152 Martinsried | Germany
Tel.: 0049 (0)89 700 961 999 | FAX: 0049 (0)89 700 961 998 | www.sirion-biotech.de